Comparison of FOLFIRINOX and gemcitabine with nab-paclitaxel in metastatic pancreatic cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.

被引：0
|
作者：
Lee, Jong-Chan
Shin, Dong Woo
Yang, Se Yeol
Kim, Min Jae
Kim, Jaihwan
Woo, Sang Myung
Lee, Woo Jin
Choi, Kui Son
Jung, Jae Hyup
Kang, Jingu
Hwang, Jin-Hyeok
机构：
[1] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[4] Natl Canc Ctr, Ctr Liver Canc, Goyang, Gyeonggi, South Korea
[5] Natl Canc Ctr, Seoul, South Korea
[6] Hallym Univ, Med Ctr, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15762
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15762
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [22] Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival
    Pacheco-Barcia, V.
    France, T.
    Zogopoulos, G.
    Bouganim, N.
    Donnay, O.
    Alcindor, T.
    Mondejar Solis, R.
    Guo, K.
    Martin, E.
    Colomer, R.
    Asselah, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
    Cho, In Rae
    Kang, Huapyong
    Jo, Jung Hyun
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Song, Si Young
    An, Chansik
    Park, Mi-Suk
    Bang, Seungmin
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (02) : 182 - 194
  • [24] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
    In Rae Cho
    Huapyong Kang
    Jung Hyun Jo
    Hee Seung Lee
    Moon Jae Chung
    Jeong Youp Park
    Seung Woo Park
    Si Young Song
    Chansik An
    Mi-Suk Park
    Seungmin Bang
    World Journal of Gastrointestinal Oncology, 2020, 12 (02) : 182 - 194
  • [25] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] FOLFIRINOX versus gemcitabine nab-paclitaxel for advanced pancreatic cancer: KU Cancer Center experience.
    Kasi, Anup
    Middinti, Akshay
    Cao, An
    Vekaria, Pratikkumar
    Patel, Devangi
    Subramaniam, Dipti
    Chen, Guoqing J.
    Saeed, Anwaar Mohammed
    Paluri, Ravi Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H. Ko
    Thach-Giao Truong
    Emily Kantoff
    Kimberly A. Jones
    Elizabeth Dito
    Anna Ong
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 875 - 881
  • [28] Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
    Winer, Arthur
    Handorf, Elizabeth
    Dotan, Efrat
    JNCI CANCER SPECTRUM, 2021, 5 (05)
  • [29] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Ko, Andrew H.
    Truong, Thach-Giao
    Kantoff, Emily
    Jones, Kimberly A.
    Dito, Elizabeth
    Ong, Anna
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 875 - 881
  • [30] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
12345